<DOC>
	<DOCNO>NCT00236444</DOCNO>
	<brief_summary>The purpose study assess efficacy safety risperidone maintenance therapy prevent symptom relapse child adolescent conduct disruptive behavior disorder , initially respond well treatment .</brief_summary>
	<brief_title>A Study Efficacy Safety Risperidone Prevention Relapse Children Adolescents With Conduct Other Disruptive Behavior Disorders</brief_title>
	<detailed_description>This randomize , double-blind study compare oral formulation risperidone placebo take daily 24 week child adolescent conduct disruptive behavior disorder . Patients respond treatment initial 6-week open-label phase , show continue response 12 week , must leave trial enter 24-week double-blind phase . The principal measure efficacy time symptom relapse . Relapse assess change follow measure : Conduct Problem subscale Nisonger Child Behavior Rating Form ( N-CBRF ) , measure symptom conduct disruptive behavior disorder Clinical Global Impression-Severity Illness ( CGI-Severity ) , measure overall severity illness . Efficacy assessment also include Clinical Global Impression-Change ( CGI-C ) , assessment improvement , Visual Analogue Scale troublesome symptom ( VAS-MS ) , scale range troublesome extremely troublesome , Children 's Global Assessment Scale ( C-GAS ) , assessment overall functioning . Safety evaluation include incidence adverse event , physical examination , laboratory test ( biochemistry , hematology , urinalysis ) , electrocardiogram ( ECGs ) . The study hypothesis daily treatment oral formulation risperidone , compare placebo , result clinically significant difference time relapse , well tolerated child adolescent conduct disruptive behavior disorder . Oral risperidone solution ( 1milligram [ mg ] /milliliter [ ml ] ) , daily 36 week . Patients weigh least 50 kilogram start 0.5 ml/day may increase to.1.5 ml/day . Patients 50kg start 0.25ml/day may increase 0.75ml/day ( maximum ) .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Attention Deficit Disorder Hyperactivity</mesh_term>
	<mesh_term>Mental Disorders</mesh_term>
	<mesh_term>Problem Behavior</mesh_term>
	<mesh_term>Attention Deficit Disruptive Behavior Disorders</mesh_term>
	<mesh_term>Risperidone</mesh_term>
	<criteria>Patients must meet criterion Diagnostic Statistical Manual Mental Disorders , 4th edition ( DMS IV ) Conduct Disorder , Oppositional Defiant Disorder , Disruptive Behavior Disorder Not Otherwise Specified Have score &gt; =24 Conduct Problem subscale Nisonger Child Behavior Rating Form ( NCBRF ) Have significant untreated unstable medical illness diabetes hypertension , serious illness liver , kidney , significant disturbance cardiac , pulmonary , gastrointestinal , endocrine , neurological system . Patients meet DSMIV criterion : Pervasive Developmental Disorder schizophrenia psychotic disorder Tourette 's Disorder Generalized Anxiety Disorder Major Depression Moderate severe mental retardation Substance Dependence Patients history neuroleptic malignant syndrome , rare psychotropicdrug reaction , may characterize confusion , reduce consciousness , high fever pronounce muscle stiffness Hypersensitivity intolerance risperidone Pregnant nursing female , lack adequate contraception</criteria>
	<gender>All</gender>
	<minimum_age>5 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>November 2010</verification_date>
	<keyword>Child</keyword>
	<keyword>adolescent</keyword>
	<keyword>disruptive behavior disorder</keyword>
	<keyword>risperidone</keyword>
	<keyword>antipsychotropic agent</keyword>
</DOC>